基于循环节律的癌症治疗在随机临床试验中
1UniSA Allied Health & Human Performance, University of South Australia, Adelaide, Australia.
Expert review of anticancer therapy
|December 21, 2023
概括
时间疗法,或基于昼夜节律的疗法,在个性化癌症治疗方面表现有前途. 然而,试验设计的差异和缺乏性别考虑阻碍了这一领域的进展.
科学领域:
- 在瘤学瘤学.
- 时间生物学 时间生物学
- 个性化医疗是个性化的医疗.
背景情况:
- 2017年诺贝尔奖强调了生物钟的分子机制.
- 基于循环节律的疗法 (时间疗法) 正在在瘤学中获得吸引力.
- 临床试验显示,在各种癌症类型中,包括头癌,肺癌,结肠直肠癌和宫癌,有前途.
研究的目的:
- 审查各种瘤部位的慢性治疗随机临床试验.
- 评估 chrono-oncology 在推进个性化癌症治疗中的证据基础.
主要方法:
- 在Pubmed/Medline数据库中进行文献搜索.
- 包括来自clinicaltrials.gov.gov的数据.
- 系统地对随机试验进行对比和评估.
主要成果:
- 目前的随机试验提供了证据,证明时间疗法在个性化癌症治疗中的作用.
- 试验方法存在显著的异质性,包括治疗时间和结果评估.
- 性别是一个关键的,但经常被忽视的,影响治疗反应的变量.
结论:
- 时间疗法具有个性化瘤治疗的潜力.
- 需要对试验设计和结果测量的标准化.
- 纳入性别作为一个变量对于优化慢性疗法疗效至关重要.
相关概念视频
Combination Therapies and Personalized Medicine
4.9K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
4.9K
Circadian Rhythms and Gene Regulation
4.1K
The biological clock is involved in many aspects of regulating complex physiology in all animals. It was in 1935 when German zoologists, Hans Kalmus and Erwin Bünning, discovered the existence of circadian rhythm in Drosophila melanogaster. However, the internal molecular mechanisms behind the circadian clock remained a mystery until 1984, when Jeffrey C. Hall, Michael Rosbash, and Michael W. Young discovered the expression of the Per gene oscillating over a 24-hour cycle. In subsequent...
4.1K
Inhibition of Cdk Activity
4.8K
The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
4.8K
Targeted Cancer Therapies
7.6K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.6K
Cancer Therapies
7.7K
Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
7.7K
Positive Regulator Molecules
5.5K
Mitotic cell division results in daughter cells that exactly resemble the parent cell. However, errors in the DNA replication or distribution of genetic material may lead to genetic mutations that may be passed down to every new cell formed from the resulting abnormal cell. Propagation of such mutant cells is restricted through checkpoint mechanisms present at different stages of the cell cycle. These checkpoints involve regulator molecules that either promote or demote cell cycle events.
5.5K


